Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression

AIDS

Volumn 18, Issue 13, 2004, Pages 1795-1804

  Phillips, Andrew N ^a   Ledergerber, Bruno ^b   Horban, Andrzej ^c   Reiss, Peter ^d   Chiesi, Antonio ^e   Kirk, Ole ^f   Mulcahy, Fiona ^g   Fisher, Martin ^h   Machala, Ladislav ⁱ   Lundgren, Jens D ^f  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c SP ZOZ Wojewodzki Szpital Zakazny Centrum Diagnostyki i Terapii AIDS Warszawa   (Poland)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^f HVIDOVRE HOSPITAL   (Denmark)

^g ST JAMES S HOSPITAL   (Ireland)

^h ROYAL SUSSEX COUNTY HOSPITAL   (United Kingdom)

ⁱ UNIVERSITY HOSPITAL BULOVKA   (Czech Republic)

Author keywords

Abavacir; Cohort study; Efavirenz; Nelfinavir; Nevirapine; Observational study; Viral load; Viral rebound; Viral suppression; Virological failure

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENCE RISK; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS INACTIVATION; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DIDEOXYNUCLEOSIDES; FEMALE; HIV INFECTIONS; HUMANS; MALE; NELFINAVIR; NEVIRAPINE; OXAZINES; PROSPECTIVE STUDIES; VIRAL LOAD;

EID: 4444249550     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00008     Document Type: Article

References (44)

1. Lampe FC, Youle MS, Sabin CA, Mocroft A, Chaloner C, Tyrer M, et al. Recent changes in antiretroviral treatment use, virological suppression, and immunosuppression in a complete HIV clinic population. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 477M].
2. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, et al. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004, 189:51-60.
3. Johnson V, Shafer R, Smeaton L, DeGruttolla V, Winters M, Hazelwood J, et al. Relative superiority of an initial antiretroviral strategy is not determined only by frequency of emergence of HIV drug resistance and cross-resistance. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 662].
4. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999, 353:863-868.
5. Paredes R, Mocroft A, Kirk O, Lazzarin, SE Barton, J. van Lunzen, TL, et al. Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study. Arch Intern Med 2000, 160:1123-1132.
6. Staszewski S, Miller V, Sabin CA, Carlebach A, Berger A-M, Weidemann E, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 1999, 13:367-373.
7. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, Piroth L, et al. Predictors of virological rebound in HIV-1 infected patients initiating a protease inhibitor-containing regimen. AIDS 2002, 16:21-29.
8. Mocroft A, Devereux H, Kinloch-de-Loes S, Wilson D, Madge S, Youle M, et al. Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. AIDS 2000, 14:1545-1552.
9. Phillips AN, Staszewski S, Lampe F, Youle MS, Klauke S, Bickel M, et al. Human immunodeficiency virus rebound after suppression to < 400 cps/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002, 186:1086-1091.
10. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1 infected patients with undetectable plasma HIV-1 RNA. AIDS 2001, 15:1517-1526.
11. Opravil M, Hirschel B, Lazzarin A, Furrer H, Chave J-P, Yerly S, et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in HIV infection. J Infect Dis 2002, 185:1251-1260.
12. Mocroft A, Ruiz L, Reiss P, Ledergerber B, Katlama C, Lazzarin A, et al. Virological rebound after suppression on highly active antiretroviral therapy. AIDS 2003, 17:1741-1751.
13. Kempf DJ, Rode RA, Xu Y, Sun E, Heath-Chiozzi ME, Valdes J, et al. The duration of viral supression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998, 12:F9-F14.
14. Raboud JM, Montaner JSG, Conway B, Rae S, Reiss P, Vella S, et al. Suppression of plasma viral load to < 20 counts/ml is required to achieve a long term response to therapy. AIDS 1998, 12:1619-1624.
15. Phillips AN, Miller V, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, et al. Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals. AIDS 2001, 15:2379-2384.
16. Lampe FC, Johnson MA, Lipman M, Loveday C, Youle M, Ransom D, et al. Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 counts/ml followed for up to 4 years. AIDS 2003, 17:768-770.
17. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with HIV infection and long-lasting suppression. Clin Infect Dis 2002, 34:504-510.
18. Katlama C, Fenske S, Gazzard B, Lazzarin A, Clumeck N, Mallalos J, et al. TRIZAL study: switching from successful HAART to trizivir: 48 weeks efficacy, safety and adherence results. HIV Med 2003, 4:79-86.
19. Martinez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med 2003, 349:1036-1046.
20. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, et al. Antiretroviral treatment simplification with nevirapine in protease-inhibitor- experienced patients with HIV-associated lipodystrophy. J AIDS 2001, 27:229-236.
21. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz J, Gonzalez-Lahoz J, et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 2000, 14:807-812.
22. Easterbrook PJ, Newson R, Ives N, Pereira S, Moyle G, Gazzard BG. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J AIDS 2001, 27:350-364.
23. Lucas GM, Chaisson RE, Moore RD. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. AIDS 2001, 15:1679-1686.
24. Ghani AC, Henley WE, Donnelly CA, Mayer S, Anderson RM. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. AIDS 2001, 15:1133-1142.
25. Perez-Elias MJ, Moreno A, Moreno S, Antela A, Dronda F, Munoz V, et al. Differences in durability of treatment with initial PI-based regimens. HIV Clin Trials 2003, 4:391-399.
26. Rey D, Schmitt MP, Partisani M, Hess-Kempf G, Krantz W, de Mautort E, et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J AIDS 2001, 27:459-462.
27. Dieleman JP, Sturkenboom MCJM, Wit FW, Jambroes M, Mulder J-W, ten Veen JH, et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among HIV-infected patients with virus suppression. J Infect Dis 2002, 185:1261-1268.
28. Moyle GJ, Gazzard BG. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis. AIDS 2002, 16:1086-1087.
29. Chiesa E, Bini T, Adorni F, Capetti A, Rizzardini G, Faggion I, et al. Simplifications of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes. Antiviral Ther 2003, 8:27-35.
30. Hirschel B, Flepp M, Bucher HC, Zellweger C, Telenti A, Wagels T, et al. Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 2002, 16:381-385.
31. Bucher HC, Kofler A, Nuesch R, Young J, Battegay M, Opravil M. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS 2003, 17:2451-2459.
32. Gulick RM, Ribaudo HJ, Shikuma CM, Lustgarten S, Meyer WA, Klingman K, et al. ACTG 5095: a comparative study of 3 protease inhibitor-sparing antiretroviral regimens for the initial treatment of HIV infection. N Engl J Med 2003, 350:1850-1861.
33. Robbins GK, de Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med 2003, 349:2293-2303.
34. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d'Arminio Monforte A et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003, 362:22-29.
35. Kirkwood BR, Sterne JAC. Essential Medical Statistics, 2nd edn. Oxford: Blackwell Science; 2003.
36. Collaboration of HIV Cohorts. Pre- and within-HAART nucleoside analogue use and viral load rebound on HAART. J Infect Dis 2004, in press.
37. Albrecht MA, Bosch RJ, Hammer SM, Liou S-H, Kessler H, Para MF, et al. Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med 2001, 345:398-407.
38. Borroto-Esoda K, Harris J, Waters J, Hinkle J, Shaw A, Quinn J, et al. Baseline genotype as a predictor of virological failure in patients receiving emtricitabine once daily or stavudine twice daily in combination with didanosine and efavirenz. Eleventh Conference on Retroviruses and Opportunistic Infections. San Francisco, February 2004 [abstract 672].
39. Le Moing V, Peytavin G, Journot V, Cottalorda J, Bouvet E, Chene G, et al. Plasma levels of indinavir and nelfinavir at time of virologic response may have a different impact on the risk of further virologic failure in HIV-infected patients. J AIDS 2003, 34:497-499.
40. Phillips AN, Pradier C, Lazzarin A, Clotet B, Goebel F-D, Hermans P, et al. HIV viral load outcome of non-nucleoside reverse transcriptase inhibitor-containing regimens for 2203 mainly antiretroviral-experienced patients. AIDS 2001, 15:2385-2395.
41. van Leth F, Hassink E, Phanuphak P, Miller S, Gazzard B, Cahn P, for the 2NN study group. Results of the 2NN Study: a randomized comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine alone, efavirenz alone or both drugs combined, together with stavudine and lamivudine. Tenth Conference on Retroviruses and Opportunistic Infections. Boston, February 2003 [abstract 176].
42. Manfredi R, Chiodo F. Limits of deep salvage antiretroviral therapy with nelfinavir plus either efavirenz or nevirapine, in highly pre-treated patients with HIV disease. Int J Antimicrob Agents 2001, 17:511-516.
43. Phillips AN, Grabar S, Tassie J-M, Costagliola D, Lundgren JD, Egger M, for the EuroSIDA, the French Hospitals Database on HIV and the Swiss HIV Cohort Study Groups. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. AIDS 1999, 13:2075-2082.
44. Sabin CA. The role of observational studies in assessing the impact of antiviral therapies. Curr Opin Infect Dis 2000, 13:631-635.